November 2015 Issue of The Medicine Maker

Round and round she goes, where she stops nobody knows. How will the current merger and acquisition fever affect the industry?

Can lettuce really help biopharmaceuticals turn over a new leaf? Researchers certainly think so.

How to dress drugs to help them survive in the bloodstream.

Can certain buzzwords really sway public perceptions of a new drug?

Could an ionic liquid–drug system help solve drug insolubility?

A newly approved oncolytic immunotherapy takes on cancer using a live modified herpes virus

The 2015 Nobel Prize in Physiology or Medicine praises advances in parasitic tropical diseases.

Should product innovation or process innovation come first in biopharmaceuticals?

Changing your company name takes more than putting a new sign on the door.

What if we could treat bacterial infection earlier and without adding to drug resistance?

In an industry as diverse as pharmaceuticals, there is much that different disciplines can learn from each another.

“The best-laid schemes o’mice an’ men” often go awry – and that can apply to your outsourcing plans.

Starting a bioanalytical research company after years working for Big Pharma has been daunting…

Advanced digital technologies are sweeping through the world and changing the way we live our lives and do business.

We sit down with Siu Ping Lam, Director of Licensing Division at the UK's Medicines and MHRA.

The challenges of battling bottlenecks in downstream processing. Sometimes a fresh pair of eyes can find new and surprising solutions.

New technologies for extractables and leachables testing of small molecules and biopharmaceuticals.

A case study involving the formulation development of a monoclonal antibody is presented to detail the utility and potential limitations of DSC in support of preformulation for a variety of protein products.

This study shows how rheology and particle size measurements can be used to characterize the physical properties of HA dermal fillers.

In this report, we illustrate the utility of calorimetry in making better laboratory decisions.

The rapid growth of the therapeutic antibody market has increased the interest in modeling of the antibody structure...

Protein interactions define a large fraction of the validated targets for drug development including cancer, diabetes, infection and autoimmune diseases.